Nanobac Pharmaceuticals, Incorporated
NNBP · OTC
12/31/2007 | 9/30/2007 | 6/30/2007 | 3/31/2007 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -24.8% | 138.9% | -51.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 15.5% | 19.7% | 21.8% | 15% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $0 | $0 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | -$1 | $3 |
| Operating Income | $1 | $1 | $1 | $3 |
| % Margin | 26,154% | 9,218.2% | 27,957.1% | 51,028.2% |
| Other Income/Exp. Net | -$2 | -$1 | -$1 | -$6 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$1 | -$4 |
| % Margin | -26,718.6% | -14,387.4% | -29,463.9% | -76,949.7% |
| EPS | 0 | -0.003 | -0.003 | -0.017 |
| % Growth | 100% | -17.2% | 82.4% | – |
| EPS Diluted | 0 | -0.003 | -0.003 | -0.017 |
| Weighted Avg Shares Out | 0 | 247 | 247 | 233 |
| Weighted Avg Shares Out Dil | 0 | 247 | 247 | 233 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$0 | $1 | -$2 |
| % Margin | -23,548.4% | -7,246.1% | 32,697.5% | -48,700.9% |